Please login to the form below

Not currently logged in
Email:
Password:

Restasis

This page shows the latest Restasis news and features for those working in and with pharma, biotech and healthcare.

Shire rebuffs Takeda bids, as Allergan bows out

Shire rebuffs Takeda bids, as Allergan bows out

a bid to reduce costs as it faces tougher competition for dry eye treatment Restasis, its second-biggest product after Botox.

Latest news

More from news
Approximately 3 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    In second position, Allergan experienced modest sales growth of 2.3%. “Allergan’s main ophthalmology product - Restasis - is the go-to treatment for dry eye, but is due to go off

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Indians scalp cowboys in patent war

    It involves an unlikely alliance with a native American tribe.  . How?  . To defend its dry eye treatment Restasis (ciclosporin) against generic competition, Allergan has transferred the patent to the St Regis ... The Restasis case is not so much an

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics